|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.AT |
First Approval Date03 Feb 1998 |
|
MechanismSodium channels blockers |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismPotassium channel blockers |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized Phase III Study Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF to Epirubicin and Docetaxel + G-CSF as Neoadjuvant Treatment for Early HER-2 Negative Breast Cancer and Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF ± Trastuzumab to Epirubicin and Docetaxel + G-CSF ± Trastuzumab as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer
Primarily, this clinical investigation compares the rates (percentages) of pathological complete remissions attained at the time of final surgery following 6 cycles each of epirubicin + docetaxel + capecitabine-containing chemotherapy ± trastuzumab (in HER-2 positive disease) vs. epirubicin + docetaxel-containing chemotherapy ± trastuzumab (in HER-2 negative disease).
100 Clinical Results associated with EBEWE Pharma Ges.m.b.H. Nfg.KG
0 Patents (Medical) associated with EBEWE Pharma Ges.m.b.H. Nfg.KG
100 Deals associated with EBEWE Pharma Ges.m.b.H. Nfg.KG
100 Translational Medicine associated with EBEWE Pharma Ges.m.b.H. Nfg.KG